Investor Presentation

2022 Annual Report

Prepared in accordance with China Accounting Standards



Performance Highlights and Financial Review

Strengths and Key Growth Drivers

Pharmaceutical

Med Tech

Healthcare Services

Appendix

Performance Highlights and Financial Review

Performance Highlights (1/3)

Revenue



Mainly due to new launches in the past

few years

Revenue from regions and countries outside **Chinese Mainland**

RMB13,938 million (+2.49% YoY)

Revenue from regions and countries outside Chinese Mainland accounts for 31.7% of the total revenue

Net profit after one-off loss

RMB3,873 million (+18.17% YoY)

> Mainly due to the solid revenue growth and effective control of marketing expenses

Net operating cash flow



Mainly due to the cash flow contribution from revenue growth and recurring profit during the reporting period

Revenue from new launches in the past few years

% Pharmaceutical Revenue >30% (>25% in 2021)

> Innovative drugs and biosimilars contributes nearly RMB10 billion of the revenue

MSCI-ESG



Improved from BBB to A, leading in the industry



Performance Highlights (2/3)

Serplulimab injection (PD-1) is approved for MSI-H, sqNSCLC and ES-SCLC in Chinese Mainland; SCLC was granted with Orphan-drug Designation from FDA and EC; the MAA of SCLC was accepted by the EMA*

Azvudine tablet has been commercialized in Chinese Mainland and included in the 2022 NRDL

Yi Kai Da (CAR-T) LBCL second



Performance Highlights (3/3)

Organizational Restructuring

Talent Led R&D

Clarifying business boundaries; subdivided Pharmaceutical into Innovative Medicines Division, Established Medicines Manufacturing & Supply Division and Vaccine Division; integrating R&D, marketing and commercialization under headquarter management; gathering resources to develop quality business

Optimizing R&D decision making

mechanism; setting key decision making steps GT1-GT6 for studies according to the R& D stages; making project decisions through Scientific committee, Clinical and Registration Committee and R& D Management Committee

Numbers of senior scientists and C-level talents joined Fosun Pharma, covering early R&D, CMC, clinical medicine and clinical operations

Constructing Scientific Advisor Board (SAB),

bringing in former corporate executives and academicians, scientists, clinical leaders and regulatory experts from well-known universities

Industry Chain Integration Capabilities

Case: Azvudine tablet

Within 5 months:

Selected and licensed in Azvudine tablet

Obtained emergency conditional approval in Chinese Mainland to treat adult patients with normal type COVID-19

Established professional sales team to commercialize in Chinese Mainland

Leveraged advantages in distribution network and logistics to rapidly expand sales channels

Collaborated with multiple manufacturers to secure supply

Delivered 6.74 million bottles of Azvudine tablet by the end of 2022



Financial Review

Key Financials (RMB million)	2021	2022	ΥοΥ	Expense Structure	2021	2022	Key Indicators	2021	2022
Revenue	39,011	43,952	12.7%	Gross Margin	48.1%	47.3%	Cash and bank balances	10,317	16,241
Net profit attributable to shareholders	4,729	3,731	-21.1%	Colling and Distribution	00.00/	20.0%			
Net profit after one-off loss	3,277	3,873	18.2%	Selling and Distribution	23.3%	20.9%	Net asset attributable to shareholders (RMB million)	39,196	44,582
Net operating cash flow	3,938	4,218	7.1%	Administrative	8.3%	8.7%		1.04	4.00
R&D Expenditure	4,978	5,885	18.2%	R&D	9.8%	9.8%	Current ratio		1.06
R&D Expense	3,837	4,302	12.1%				Quick ratio	0.85	0.85
Basic EPS (RMB/share)	1.85	1.43	-22.7%	Finance	1.2%	1.5%			
Dividend Payout Ratio (Subject to approval by the shareholders)	30%	30%	-	Gross Margin minus Selling and Distribution	24.8%	26.4%	Debt-to-asset ratio	48.2%	49.5%

Note :

Note: nonrecurring loss RMB142 million (-1,593 million YoY), mainly due to market fluctuations of BNTX and other stocks held by the Group; the net effect of BNTX disposal and fair value changes results approximately RMB1 billion one-off loss; realized RMB3,731 million (-21.10% YoY) net profit attributable to shareholders for the reporting period

<u>The decrease of Gross Margin was mainly due to:</u> 1) the lower gross margins on overseas sales of third party personal protective products for COVID-19; 2) the unit price increase of some core products due to the increase in labor costs and raw materials; 3) but the GM of Pharma business increased by 2.96 pct due to the continuous optimized product structure <u>The decrease of selling and distribution rate was caused by the combined</u> <u>impact of :</u> 1) continuously strengthen the control of sales expanse; 2) the decreased selling and distribution rate of volume based purchasing products;3) spend on market development and sales team for new launches in the past few years including Serplulimab injection (PD-1)

Note : the increase of cash and bank balances was mainly due to the raised RMB4.48 billion from nonpublic placement of A-Shares in July 2022. The raised fund is for 1) innovative drug clinical trials, license-in and launch; 2) construction manufacturing base for API and formulation; 3) replenishment working capital

Financial Review - Segments Breakdown

Pharmaceutical

Revenue RMB 30,812 million (+6.60% YoY); Segment results¹ RMB3,795 million (+28.04% YoY); Profit RMB3,413 million² (+29.77% YoY)

Revenue change was mainly driven by: Rapid growth from new launches in the past few years Gland Pharma revenue -6% YoY⁵ due to the suspension of production line for upgrade and insufficient supply of packaging materials Comirnaty (mRNA COVID-19 vaccine)

sales -30% YoY

The growth of Segment results and Profit was mainly driven by:

Increased profit margin with improved product portfolio

The decrease of selling and distribution rate

Med Tech

Revenue RMB6,949 million (+17.03% YoY); Segment results¹ RMB521 million (+11.87%³ YoY); Profit RMB771 million (+2.33%³ YoY)

Growth was mainly driven by:

Strong growth of medical aesthetics business in key markets including North America and Europe through new launches and distribution channel expansion Sales of COVID-19 Antigen Test and other new launches

Healthcare Services

Revenue RMB6,080 million (+33.56%⁴ YoY); Segment results¹ RMB622 million loss (RMB255 million less YoY);Profit RMB792 million loss (RMB359 million less YoY)

Growth was mainly driven by: Growth from online services and revenue recovery from offline hospitals

The decline of Segment Results and Profit was mainly caused by: Investment in online business Periodic decrease in diagnosis and treatment volume of hospitals Initial loss of newly opened hospitals

Note 1: Segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses

Note 2: Pharmaceutical segment profit excludes the effect on sales of BNTX shares

Note 3: Med Tech growth is the YoY growth excludes the impact from equity transfer of Yaneng Bioscience in 2021

Note 4: Healthcare Services segment revenue growth is the YoY growth excludes the impact from Guangzhou Xinshi Hospital acquisition in 2022

Note 5: Based on the financial statements of Gland Pharma in its reporting currency



Strengths and Key Growth Drivers




Upgraded Innovative Pipeline & System Development - R&D Strategy

Core Technology Platform

Small Molecule, Antibody/ADC, RNA, Cell Therapy

Strengthened small molecule R&D capabilities

Established R&D capabilities of novel antibody including monoclonal antibody, bispecific antibody and ADC





global R&D system which is resultoriented and innovation-driven

Core R&D System and Capabilities

Efficient and comprehensive -to- R&D capabilities from project management to market launch

Clinical value-oriented drug innovation, FIC+BIC accounts for over 50% of the pipeline products

Accelerated the R&D of competitive product with dynamic evaluation



Upgraded Innovative Pipeline & System Development - Core Products

Launched Core Product Core Product Pipeline Serplulimab injection (PD-1) Etelcalcetide Ejilunsai injection (CAR-T) Serplulimab injection (PD-1) Ejilunsai injection (CAR-T) Second-line LBCL HPT ESCC MSI-H, sqNSCLC, ES-SCLC Third-line LBCL NDA Trastuzumab (HER2) - U.S. Avatrombopag Maleate Opicapone COMT Breast Cancer ITP Parkinson syndrome Rituximab injection (CD20) Trastuzumab injection(HER2) Lymphoma, RA Breast Cancer Serplulimab injection (PD-1) Tenapanor FCN-437 CDK4/6 Neo-/adjuvant treatment of (NHE3 small molecule) Breast Cancer ESRD-HD. IBS-C Ph3 gastric cancer Netupitant and Palonosetron Innovative Azvudine **RT002 SAF-189** Chemo-induced Products FCN-1502 (HER2-ADC) COVID-19 Treatment (long-lasting botulinum toxin) nausea and vomiting (ALK&ROS1) Breast Cancer, etc. GL CD NSCLC Avatrombopag Maleate **Apremilast** FCN-338 Bcl-2 **FCN-159** Ph2 **ET-26** (MEK small molecule CLDT Psoriasis Hematological malignancies Anesthesia Type I Neurofibroma R/R BCL Keverprazan Hydrochloride Antimalarial Series Other Keverprazan Hydrochloride Global FKC-889 CAR-T Chinese Mainland Including Artesunate Pivotal MCL DU. RE Duodenal Ulcer, Reflux Esophagitis Anti-malarial Studies 24-Valent Pneumococcal 13-Valent Pneumococcal mRNA COVID-19 Vaccine **Bivalent mRNA COVID-19 Vaccine** Ph3 Ph1 **Conjugate Vaccine Conjugate Vaccine** Hong Kong, Macau, Taiwan regions Hong Kong, Macau, Taiwan regions Pneumococcal Disease Prevention Pneumococcal Disease Prevention COVID-19 Prevention COVID-19 Prevention Vaccines Freeze-dried Human Rabies Vaccine Human Rabies Vaccine 4-Valent Influenza Vaccine Ph3 Influenza Vaccine Ph3 (Vero Cells) (Vero Cells) Influenza Prevention Influenza Prevention Rabies Prevention Rabies Prevention 27 generic drugs / indications were approved in Filed 30 generic drugs / indications NDA in Chinese Mainland Generics R&D pipeline: 118 generic drugs, 21 consistency evaluation Chinese Mainland / Hong Kong region / the U.S. in 2022 Note: updated to March 31st 2023




Note:


Oncology Drugs

Non-oncology drugs

Access to Opportunities Through In-house R&D, Incubation, Strategic M&A and Collaboration



Lean Management System



Integrating API and formulation manufacturing and focusing on key pipelines

Building a regionalized manufacturing center around Xuzhou Area, vertically integrating Sino API facility with Xuzhou formulation facility to achieve intensive production capacity, covering multiple dosages and disease areas

Chongqing facility and Changde facility have completed the first stage construction; Sino API facility and Xuzhou formulation facility have completed the tech transfer and validation for the first batch. The increased capacity will support future commercial manufacturing

Fosun Ecosystem/Entrepreneurship System, lean management and improvement of daily management system

Achieved closed-loop procurement management through SRM system, promoting standardization, digitalization and intelligence business

Improved R&D and clinical trials management, cost control and R&D team synergy by implementing an end-to-end R&D management platform based on in-house developed INNOX digital platform

Incremental FES projects in 2022 covering quality, cost, efficiency, cycle time, R&D, etc.

Commercialization integration and optimization to control sales expenses and improve sales efficiency

Commercialization team matches with current product portfolio; 6,000 people in pharmaceutical commercialization team covers oncology and non-oncology areas, OBM broad market team, OTC, online channels and teams in Africa, India and the U.S.

Strengthening effective control of sales expenses, with the growth rate of sales expenses lower than the growth rate of revenue; the sales expense ratio was 20.87% in 2022 (-2.46 pp YoY)

Key products cost reduction and efficiency improvement, preparing for procurement and transforming marketing model



Global Operation (1/2)

15





Figure number: GS(2016)1666

Global Operation (2/2)



Corporate Governance Sustainable Development

MSCI-ESG Rating Upgrade




Included in the HSCASUS and HSMHSUS





Pharma - Performance



Note 1: segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses Note 2: pharmaceutical profit excludes the effect on sales of BNTX shares

Pharma - Core Product Revenue in Different Therapeutic Areas

Anti-tumor and Immune Modulation

RMB5,522 million 26%*

Revenue increase from Trastuzumab Injection (HER2), Avatrombopagmaleate Tablets, Adalimumab injection and from new launches in the past few years including Serplulimab Injection (PD-1) and Netupitant-Palonosetron

Anti-infection

RMB8,582 million 40%*

Mainly due to the combined effect of the decrease in the sales volume of Comirnaty (mRNA COVID-19 vaccine) and Micafungin, the revenue contribution from new products Azvudine tablets, Cravit (levofloxacin tablets and levofloxacin injection)

Metabolism and Alimentary System

RMB2,883 million 13%* -0.24% YoY

Mainly due to the impact of the execution of centralized procurement for Thioctic acid injection and Glutathione for injection

Cardiovascular System

RMB2,115 million 10%* +6.12% YoY

Mainly due to the increase in the sales volume of heparin series preparations

Central Nervous System

RMB1,003 million 5%* -11.79% YoY

Mainly due to the decline in sales volume of deproteinised calf blood serum injection

APIs and Intermediate Products

RMB1,248 million 6%* +9.96% YoY

Mainly due to the increase in the sales volume of amino acid series



Note: represents core product revenue in single therapeutic area / sum of core product revenue in all therapeutic areas


Pharma - R& D Expenditure

R&D expenditure drives product portfolio optimization

Phama R&D expenditure was RMB5,097 million (+13.62% YoY) in 2022, accounts for over 85% of the total R&D expenditure and 16.47% of the pharma revenue; Pharma R&D expense was RMB3,552 million, accounts for 11.53% of the pharma revenue

new launches in the past few years including Serplulimab injection (PD-1), Trastuzumab injection (HER2), Avatrombopag tablets and Azvudine tablets accounts for over 30% of the pharma revenue, optimizing product portfolio

Over 260 pipeline drugs in innovative drugs, biosimilars, generic drugs, consistency evaluation items, etc.; received 249 applied pharma patents, including 16 U.S. patent applications, 17 PCT applications and 48 licensed invention patents in 2022



2021 2022



Pharma Key Progress - Serplulimab Injection

The first PD-1 inhibitor approved for first-line treatment of SCLC



$\mathsf{RMB}340 \text{ million}$

2022 Revenue (Launched for 9 months)



Target: PD-1 Approved Indications in Chinese Mainland: MSI-H

sq N SCLC

ES-SCLC

Overseas Progress

SCLC is granted with Orphan-drug

Designation from FDA and EC

Initiated ES-SCLC head-to-head

bridging in the U.S.

Outstanding Results

Serplulimab + chemo (ES-SCLC) randomized, double-blind, median progression, global multi-center Phase 3 clinical data: Median OS 15.4 months, vs 10.9 month with placebo; 2 year OS rate 43.1%, vs 7.9% with placebo

&

journals including The Journal of the American Medical Association (JAMA), Nature Medicine and British Journal of Cancer



Quick Market Access and Accelerated Market Penetration

Completed tenders on procurement platforms in 27 provinces; covered 30% of the top 110 hospitals

Commercialization team of about 400 people with experience in oncology drugs market

Established efficient distribution network; maximized accessibility by leveraging DTP pharmacies and infusion centers




Pharma - Global Commercialization System



24








Medical Devices Sisram Medical

Establishing global Wellness Ecosystem based on energy-based devices and extending to injectables, aesthetic dentistry and personal care

2022 Main Progress

294.3

Revenue



Medical Devices - Intuitive Fosun

Localization Process

2017	•	Announced to form a JV with Intuitive Surgical in China in 2016 based on the long-term partnership and established Intuitive Fosun in Shanghai in 2017
2019	•	Marketing the 4th generation Da Vinci XI Surgical System
2020	+	Da Vinci Surgical System test drives in more than 10 cities across China, with more than 800 doctors from nearly 200 hospitals participated in the experience
2021	•	Da Vinci Innovation Center opened with 1,700 m ² of space to provide high-quality hands-on precision medicine training to approximately 4,000 doctors per year
2022	•	Building da Vinci Surgical Manufacturing R&D Center in Shanghai, covering about 31.2 acres
Future	↓ ↓	Localization in technology, manufacturing and services
		Made in China
		Joint R&D

Global Commercialization

Main Products

Da Vinci Surgical System



55 da Vinci Surgical Systems were installed in China in 2022. By the end of 2022, **over 300 Systems** were installed in Chinese Mainland, Hong Kong and Macau regions and completed more than 100,000 surgeries within 2022

As of June 30th 2022, **7,544 systems** were installed worldwide, with more than 55,000 doctors trained to use the system, and **performed over 10 million surgeries**.

Ion Endoluminal System

The robotic-assisted bronchoscopy platform, lon, was **approved by FDA in 2019**

The lon guided lung nodule biopsy clinical feasibility trial completed enrollment at Shanghai Chest Hospital in October 2021. It is **the first clinical trial using lon outside the United States**



Medical Diagnosis - Core Products

Medical Diagnosis 2022 Major Progress


Promoting the integration of medical diagnosis segment, constructing 6 R&D and manufacturing bases; R&D personnel account for more than 15% of the total number of Medical Diagnosis employees

F-C800p Automatic Biochemical Analyzer launched in June 2022, together with the F-i3000 Automated Chemiluminescence Immunoassay Analyzer, formed Fosun Diagnostics biochemical immunoassay pipeline to meet the clinical diagnostic testing needs

Self-developed COVID-19 Rapid Antigen Test was approved by NMPA in April 2022. It has received EU CE certification and has been included in the EU Common list of COVID-19 antigen tests and completed BfArM registration in Germany


Self-developed Monkeypox PCR Detection Kit received EU CE certification in May 2022

6 R&D and Manufacturing Bases



Strengthening R&D and manufacturing capabilities of diagnostic APIs, reagents and instruments


Integrating business





Healthcare Services

Healthcare Service - Performance



Segment Results¹ (RMB million) (RMB million) -RMB255 million3 2021 2021

Segment Profit

-433



-367

Healthcare Services - Offline Services



Covered Region

Focus on the Yangtze River Delta, the Greater Bay Area and other regions; connecting medical centers with regional medical associations; integrating hospital resources 6,333 beds¹ in hospitals

controlled by the Group by the end of 2022

Note1: Last update in December 2022 Note2: According to Ailibi ranking



Healthcare Services Integrating Online and Offline Services

Upstream: Pharmaceutical Supply



Sinopharm Performance



Actively complied with the industry transformation trend, strengthened service capability of distribution network, and ensured the steady growth of key regions and markets while continuously improving the coverage and penetration ratio of business network. The 2022 revenue from the pharmaceutical distribution segment reached RMB406.60 billion (+4.27% YoY)

guarding personal protective products for COVID-19, and further enhanced the market share. The 2022 revenue from the medical device segment amounted to RMB120.85 billion (+11.77% YoY)

Actively responded to the national strategy, undertook the new transformation and demand of separation of medical services and pharmaceutical sales, increased the allocation of resources, and made great efforts to promote the balanced development of professional pharmacies and traditional pharmacies. The 2022 revenue from retail pharmacy business reached RMB33.0 billion (+13.49% YoY)



Appendix

Large Molecules Pipeline (1/2)

Therapeu tic Area	Pro	duct	Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
				Squamous non-small cell lung cancer 1L Global multi-center clinical trial Ph3, approved in Chinese Mainland in November 2022 Extensive-stage small cell lung cancer 1L First U.S. bridging study subject had been dosed in November 2022; granted Orphan-drug Designation Chinese Mainland in January 2023						
		+Chemo	PD-1	Metastatic esophageal squamous-cell carcinoma		iniana in bandary	2023			
				Limited-stage small cell lung cancer	Global multi-center clinit				uary 2023	
	HLX10 ¹			Neo-/adjuvant treatment of gastric cancer						
	(Serplulimab		b PD-1+VEGF	Non-squamous non-small cell lung cancer 1L						
		+Bevacizumab +HLX07		Hepatocellular carcinoma 1L						
Anti-tumor				Metastatic colorectal cancer 1L						
			PD-1+EGFR	Squamous-cell carcinoma of the head and neck 2L						
				Squamous non-small cell lung cancer 1L	First subject had been d	osed in January 2	2022		•	
	HLX04-O ² ESSEX 1281		VEGF	Wet age-related macular degeneration	Global multi-center clinic first subject had been do				uary 2022;	
	HLX22	+Trastuzumab	HER2+HER 2	Gastric cancer	Initiated Ph2 clinical tria	,	•		•	
	HLX07	LX07		Solid tumors (non-small cell lung cancer, esophageal carcinoma, etc.)	Approved clinical trials t	by FDA			•	
	HLX11 Pertuzumab ³		NON HER2	Breast cancer	Global multi-center clinic	al trial Ph3; first:	subject had been dos	ed in Chinese Mainla	nd in 2022	
			ze EGFR	Metastatic colorectal cancer and squamous-cell carcinoma of the head and neck						

Note 1: granted KG Bio to develop and commercialize HLX10 in 10 countries in Southeast Asia

Note 2: granted ESSEX an exclusive license to develop, manufacture, and commercialize HLX04 in human ophthalmic therapeutic use

Note 3: granted Organon exclusive global commercialization rights except for China

Note 4: granted Jingze Biotech to commercialize HLX05 in China

Note 5: last update on 28th February 2023



Large Molecules Pipeline (2/2)

37

Therapeutic Area	Product	Target/MOA	Indication	Pre- Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
	50 (500		HER2-positive advanced malignant solid tumor					•	
	FS-1502	HER2	HER2-positive locally advanced or metastatic breast cancer				-		
	FS-1502+Serplulimab	HER2+PD-1	Advanced gastric cancer with HER2 expression					•	
	HLX14 (Denosumab) ¹		Osteoporosis	Initiated Ph3 clinical trial in Chinese Mainland in June 2022; approved to enter Ph3 clinical trial by TGA in July 2022					
Anti-tumor	HLX26	LAG-3	Solid tumors and lymphomas					r no omnour mar by	1 of 1 in 0 dig 2022
	HLX35 ²	EGFR 4-1BB	Solid tumors	Approved to enter of	clinical trials by NM	IPA in January 2022	; first subiect had be	en dosed in Chines	e Mainland in June 2
	HLX301 PD-L1 TIGIT		Solid tumors	Approved to enter clinical trials by NMPA in January 2022; first subject had been dosed in Chinese Mainland in First subject had been dosed in Australia in February 2022; Approved to enter clinical trials by NMPA in March 2022; first subject had been dosed in Chinese Mainland in Ju					
	HLX15 (Daratumumab)	CD38	Multiple myeloma	First subject had be	en dosed in Chine	ese Mainland in Febr	uary 2023		
	HLX13 (Ipilimumab)	CTLA-4	Melanoma, renal cell carcinoma and metastatic colorectal cancer						
Blood system	Recombinant Human Erythropoietin Injection (pre-filled syringe)	EPO	Anemia of renal disease						
Matakaliana	Recombinant Insulin Glargine Injection	INSR	Diabetes						
Metabolism and Digestive System	Mixed Protamine Zinc Recombinant Insulin Lispro Injection (50R)	INSR	Diabetes						
	Liraglutide Injection	GLP-1	Diabetes						
Others	RT002	Bio 1 Bio 1	Moderate to severe glabellar lines in adults (GL) Cervical dystonia (CD)	Completed the enro	Ilment of subjects	in Chinese Mainland	d in January 2022		

Note 1: granted Organon exclusive global commercialization rights except for China Note 3: last update on 28th February 2023 Note 2: granted Binacea to research, develop, manufacture and commercialize the HLX35 globally except for China (including Hong Kong, Macau and Taiwan region)

Small Molecules Pipeline (1/2)

Therapeutic Area	Project	Target/MO A	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA	
			Breast cancer (1L)	Approved to enter Ph3 clinical trial by NMPA in January 2022; Ph1 clinical trial in the U.S.						
	FCN-437c	CDK4/6	Breast cancer (2L)	s by FDA	•					
	SAE 190	ALK	Non-small cell lung cancer	Initiated Ph3 clinical trial in Chinese Mainland in January 2022; Ph1 clinical trial in the U.S.						
	SAF-189	ROS1	Non-small cell lung cancer	Approved to enter clinical trials by FDA						
	HLX-208	BRAF V600E	Solid tumors (metastatic colorectal cancer, non- small cell lung cancer, etc.) LCH and ECD5	Approved to enter Ph1b/Ph2 clinical trials by NMPA in January 2022						
	FCN-159	MEK	Jeurofibromatosis type 1 Global multi-center clinical trial							
Anti-tumor			Low-grade glioma							
Anti-tumor			Malignant melanoma							
			Arteriovenous malformation							
			Histiocytic tumor							
	YP01001	VEGFR	Advanced solid tumor							
	ECN 229		Hematological malignancies	Approved to enter Ph1	clinical trial in the U.S					
	FCN-338	BCL-2	Relapsed or refractory B-cell lymphoma							
	FH-2001	FGFR/PD- L1	Advanced malignant solid tumors				•			

Note: last update on 28th February 2023



Small Molecules Pipeline (2/2)

Therapeutic Area	Project	Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Blood System	Avatrombopag Tablet	TPO-R	Chronic idiopathic thrombocytopenic purpura				·	·	
	Tenapanor Tablet	NHE 3	End-stage Renal Disease Hemodialysis						
Metabolism	Ferric Pyrophosphate Citrate	-	Iron replacement for HD patients						
	Tenapanor Tablet	NHE 3	Irritable Bowel Syndrome with Constipation						
	FCN-342	URAT1							



Vaccine Pipeline

Product	Technology	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Freeze-dried Human Rabies Vaccine (Vero Cells)	Inactivated						
4-Valent Influenza Vaccine	Inactivated						
Human Diploid Cell Rabies Vaccine	Inactivated						
13-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
24-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
23-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
Quadrivalent Meningococcal Polysaccharide Vaccine	Multivalent Conjugate						
Tetanus Vaccine	-						
Quadravalent Meningococcal Conjugate Vaccine	Multivalent Conjugate						
Recombinant Zoster Vaccine	Insect Cells with Recombinant Baculovirus						
Recombinant Quadravalent Influenza Vaccine	Insect Cells with Recombinant Baculovirus						

Note: last update on 28th February 2023



Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun, are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com